The ones supposedly prescribed under the "preferred prescriber status"? They were the ones Dr. De silva? was going to trial on some of her pool of 3000 alledged patients from memory. The trial was to commence in December as per Company announcement. The silence suggests to me that nothing has commenced.
Is Dr. De Silva still on board so far as support for this Company goes? You would have to wonder as her professional reputation is at stake. I imagine she has been privy to all the failed deadlines, promises and possibly even the twitter/Facebook rants. Hardly the things a well regarded professional would like to be associated with. On the other hand, l have not heard of her Board resignation, so maybe its all " pending" in the usual MXC fashion.
The Notra Same University trial is due for a start too isn't it?
Just a few of the growing list of items that need updating. None of this surprises any of us though.
- Forums
- ASX - By Stock
- RGT
- I wonder how those CannEpil sales are going?
I wonder how those CannEpil sales are going?, page-3
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RGT (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.00M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3300 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
30.0¢ | 313 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 3300 | 0.310 |
2 | 3844 | 0.290 |
2 | 20000 | 0.270 |
1 | 4000 | 0.250 |
1 | 17426 | 0.205 |
Price($) | Vol. | No. |
---|---|---|
0.300 | 313 | 1 |
0.305 | 45198 | 3 |
0.315 | 2825 | 2 |
0.340 | 2115 | 2 |
0.370 | 1056 | 1 |
Last trade - 16.16pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
RGT (ASX) Chart |
Day chart unavailable